Diagnostics
We understand how critical it is to have reliable answers regarding your health. That's why we're breaking down existing barriers to these answers by making diagnostics faster, more reliable, and more accessible.
As if the preceding two years weren't eventful enough, 2022 presented a new challenge: monkeypox (MPXV).
Our Abbott Pandemic Defense Coalition worked to share information about the virus around the world as we developed an early MPXV PCR test for research use by our Coalition partners. We followed that by developing a second MPXV PCR test for use globally on our Alinity m System, our most advanced and efficient molecular system in our testing portfolio.
This fast and determined delivery of a much-needed tool to combat a potential epidemic earned the test a 2023 CES Innovation Award.
And to address a devastating condition that dates much further back than 2022, we worked to expand access to our i-STAT TBI Plasma test, which can help clinicians evaluate traumatic brain injuries — including concussions — in just 15 minutes, potentially saving time and money while increasing efficiency and knowledge in care. It's now offered in Tampa General Hospital's Emergency Department.
Trust that we're not stopping there. Transforming the way we evaluate concussions helped our i-STAT TBI Plasma test bring home a Best New Product Edison Award.
A solid start indeed.
But when it comes to improving the lives of billions across the globe — increasing access, cutting-edge innovation, affordability and convenience — we're never satisfied. We're in this pursuit for the longest run.
References
1 FreeStyle Libre 3 User's Manual.
* The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app. Use of the FreeStyle Libre 3 app requires registration with LibreView
FOLLOW ABBOTT